On April 24th Abbott the global diagnostics specialist received the CE Mark for its lab-based blood test for the detection of COVID-19 IgG antibodies.
The breakthrough will help identify people infected with Coronavirus. It will also provide more understanding of how long antibodies stay in the body and if they provide immunity. This is crucial for both Governments as well as the private sector as it determines if people on the frontline- health workers as well as other people in key roles- can safely return to work.
Thanks to the relationship with its distributor in Malta V.J. Salomone as well its close collaboration with the local Health Authorities, the Abbott COVID-19 Antibody test is already available in Malta.
“We are proud to be shipping our antibody tests immediately as it helps understand who has had the virus, leading to greater confidence as we get back to living life.” said Dr. Luigi Ambrosini, Managing Director Abbott Italy.
Abbott’s Antibody blood test demonstrated specificity and sensitivity of greater than 99 per cent 14 days or more after symptoms started.
Evaluated by procurement as “best method” Abbott’s were awarded the National Tender by the Italian Ministry of Health for epidemiological screening and they intend to distribute more than 4million tests by the end of May. At the same time, Abbott significantly scaled up its European manufacturing for antibody testing and started to ship these tests across the European continent including Malta.
Abbott’s antibody test is initially available for use on its ARCHITECT® laboratory instruments, two of which are available at Mater Dei Hospital and can run up to 100-200 tests per hour per instrument.
A global leader in infectious disease testing
Abbott has long been a global leader in infectious disease testing, including the development of the first HIV test. The company created a Global Surveillance Program 25 years ago to monitor HIV and hepatitis viruses and identify mutations to ensure the company’s tests remain up to date. Abbott also has a long-standing discovery program that identifies new or unknown pathogens and develops tests to address these new threats.
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Abbott’s portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, Nutritionals and branded generic medicines. Abbott’s 107,000 colleagues serve people in more than 160 countries.